Hepatocellular jaundice in SARS-CoV-2 and EBV coinfection: a case report.

IF 4 3区医学 Q2 VIROLOGY

Virology Journal Pub Date : 2025-08-21 DOI:10.1186/s12985-025-02865-w

Joseph H Kelly, Kenji Hamanaka, Abigail Polzin

{"title":"Hepatocellular jaundice in SARS-CoV-2 and EBV coinfection: a case report.","authors":"Joseph H Kelly, Kenji Hamanaka, Abigail Polzin","doi":"10.1186/s12985-025-02865-w","DOIUrl":null,"url":null,"abstract":"Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Epstein-Barr virus (EBV) are each individually associated with mild hepatic injury and, rarely, with hyperbilirubinemia. Coinfection is not well documented, and within available reports, mild hepatic injury has been demonstrated.Case presentation: A 25-year-old man with no significant past medical history acquired coinfection and developed transaminitis, moderate hyperbilirubinemia, and hepatosplenomegaly. The degree of transaminitis was severe and out of proportion for either SARS-CoV-2 or EBV infection. The patient was admitted to the hospital for further laboratory and imaging studies to rule out other etiologies. He was managed symptomatically and without antiviral medications. The patient's transaminase levels demonstrated a pattern of recovery on day 10 with complete normalization documented at 10 months. There were no long-term sequelae.Conclusions: While SARS-CoV-2 and EBV are each independently associated with mild hepatic injury, this case highlights a rare presentation of severe liver injury, possibly due to synergistic viral effects.","PeriodicalId":23616,"journal":{"name":"Virology Journal","volume":"22 1","pages":"289"},"PeriodicalIF":4.0000,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12369147/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Virology Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12985-025-02865-w","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"VIROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Epstein-Barr virus (EBV) are each individually associated with mild hepatic injury and, rarely, with hyperbilirubinemia. Coinfection is not well documented, and within available reports, mild hepatic injury has been demonstrated.

Case presentation: A 25-year-old man with no significant past medical history acquired coinfection and developed transaminitis, moderate hyperbilirubinemia, and hepatosplenomegaly. The degree of transaminitis was severe and out of proportion for either SARS-CoV-2 or EBV infection. The patient was admitted to the hospital for further laboratory and imaging studies to rule out other etiologies. He was managed symptomatically and without antiviral medications. The patient's transaminase levels demonstrated a pattern of recovery on day 10 with complete normalization documented at 10 months. There were no long-term sequelae.

Conclusions: While SARS-CoV-2 and EBV are each independently associated with mild hepatic injury, this case highlights a rare presentation of severe liver injury, possibly due to synergistic viral effects.

Abstract Image

查看原文本刊更多论文

SARS-CoV-2和EBV合并感染的肝细胞性黄疸1例

背景：严重急性呼吸综合征冠状病毒2 （SARS-CoV-2）和eb病毒（EBV）各自与轻度肝损伤相关，很少与高胆红素血症相关。合并感染没有很好的文献记载，在现有的报告中，已证实有轻度肝损伤。病例介绍：25岁男性，无明显既往病史，合并感染并发展为转氨炎、中度高胆红素血症和肝脾肿大。SARS-CoV-2和EBV感染的转氨炎程度严重且不成比例。患者入院接受进一步的实验室和影像学检查，以排除其他病因。对他进行了对症治疗，没有使用抗病毒药物。患者的转氨酶水平在第10天显示出恢复的模式，并在10个月时完全正常化。无长期后遗症。结论：虽然SARS-CoV-2和EBV各自独立与轻度肝损伤相关，但该病例突出了罕见的严重肝损伤，可能是由于病毒的协同作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Virology Journal 医学-病毒学

CiteScore

7.40

自引率

2.10%

发文量

186

审稿时长

1 months

期刊介绍： Virology Journal is an open access, peer reviewed journal that considers articles on all aspects of virology, including research on the viruses of animals, plants and microbes. The journal welcomes basic research as well as pre-clinical and clinical studies of novel diagnostic tools, vaccines and anti-viral therapies. The Editorial policy of Virology Journal is to publish all research which is assessed by peer reviewers to be a coherent and sound addition to the scientific literature, and puts less emphasis on interest levels or perceived impact.